胸腺上皮性肿瘤的分子生物学特征及治疗研究进展  

Research progress of molecular biological characteristics and treatment in thymus epithelial tumor

作　　者：朱楷 史慧洋 陆婧玉 朱豪华 胡兴胜 Zhu Kai;Shi Huiyang;Lu Jingyu;Zhu Haohua;Hu Xingsheng(Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100021,China)

机构地区：[1]国家癌症中心、国家肿瘤临床医学研究中心、中国医学科学院北京协和医学院肿瘤医院内科,北京100021

出　　处：《中国肿瘤临床与康复》2024年第1期9-16,共8页Chinese Journal of Clinical Oncology and Rehabilitation

基　　金：中国科学院科技智库理事会课题(EOX17816)。

摘　　要：胸腺上皮性肿瘤(TET)是一种好发于前纵隔的罕见肿瘤,主要包括胸腺瘤和胸腺癌。对于可手术切除Masaoka-Koga分期为Ⅰ~ⅢA期的TET,外科手术仍为首选治疗方式。对于复发及难治性TET推荐进行以铂类药物为主的化疗、靶向治疗和放疗。此外,由于近年来免疫治疗的发展,其也成为TET联合治疗的选择之一。但免疫治疗导致的免疫相关不良反应(irAE)限制了其应用。文章主要介绍了TET的分子生物学特征,并对TET靶向治疗和免疫治疗的新进展进行综述。Thymus neoplasm is a rare type tumor,which is frequently discovered in anterior mediastinum.Thymic epithelial tumor(TET)mainly includes two types:thymoma and thymic carcinoma.For TET patients with Masaoka-Koga stage Ⅰ-Ⅲ A,surgical excision is the most recommended treatment if oparable.While platinum-based chemotherapy,targeted therapy and radiotherapy are suitable for recurrent and refractory TET patients.Moreover,immunotherapy has achieved major breakthrough and become a rising star in TET treatment.However,immune-related adverse event caused by immunotherapy are hampering its further application.This article mainly covers research progress of molecular biological characteristics,targeted therapy and immunotherapy of TET.

关 键 词：胸腺上皮性肿瘤 分子生物学特征 免疫治疗 靶向治疗 

分 类 号：R736.3[医药卫生—肿瘤]